Novel anti-angiogenic therapies for malignant gliomas

[1]  L. Deangelis,et al.  Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma , 2009, Neurology.

[2]  P. Kelly,et al.  Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. , 2009, Journal of neurosurgery.

[3]  Denis Lacombe,et al.  Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[5]  Craig Murdoch,et al.  The role of myeloid cells in the promotion of tumour angiogenesis , 2008, Nature Reviews Cancer.

[6]  B. Garmy-Susini,et al.  Integrins in angiogenesis and lymphangiogenesis , 2008, Nature Reviews Cancer.

[7]  S. Taillibert,et al.  [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study]. , 2008, Revue neurologique.

[8]  P. Wen,et al.  Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. , 2008, Neuro-oncology.

[9]  T. Mikkelsen,et al.  Retrospective analysis of patterns of recurrence seen on MRI in patients with recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan , 2008 .

[10]  W. Mason,et al.  Enzastaurin (ENZ) versus lomustine (CCNU) in the treatment of recurrent, intracranial glioblastoma multiforme (GBM): A phase III study , 2008 .

[11]  H. Friedman,et al.  Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas , 2008 .

[12]  T. Mikkelsen,et al.  A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) , 2008 .

[13]  P. Gutin,et al.  Patterns of relapse and prognosis after bevacizumab (BEV) failure in recurrent glioblastoma (GBM) , 2008 .

[14]  Susan M. Chang,et al.  Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601 , 2008 .

[15]  S. Vandenberg,et al.  HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. , 2008, Cancer cell.

[16]  P. Wen,et al.  Bevacizumab for recurrent malignant gliomas , 2008, Neurology.

[17]  J. Gallo,et al.  Impact of Angiogenesis Inhibition by Sunitinib on Tumor Distribution of Temozolomide , 2008, Clinical Cancer Research.

[18]  D. Schiff,et al.  Reversible posterior leukoencephalopathy syndrome in cancer , 2008, Current oncology reports.

[19]  Yiting Cao,et al.  Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Fine,et al.  A Phase I Trial of Lenalidomide in Patients with Recurrent Primary Central Nervous System Tumors , 2007, Clinical Cancer Research.

[21]  P. Wen,et al.  Medical management of brain tumor patients. , 2007, Neurologic clinics.

[22]  P. Wen,et al.  Inhibition of angiogenesis and invasion in malignant gliomas , 2007, Expert review of anticancer therapy.

[23]  John Sampson,et al.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Gilbertson,et al.  Making a tumour's bed: glioblastoma stem cells and the vascular niche , 2007, Nature Reviews Cancer.

[25]  J. Rich,et al.  Cancer stem cells in radiation resistance. , 2007, Cancer research.

[26]  Christopher G Willett,et al.  Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  T. Mikkelsen,et al.  Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway , 2007, Oncogene.

[28]  A. Gregory Sorensen,et al.  Angiogenesis in brain tumours , 2007, Nature Reviews Neuroscience.

[29]  Tracy T Batchelor,et al.  Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. , 2007, Neuro-oncology.

[30]  P. Wen,et al.  A phase II trial of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma , 2007 .

[31]  T. Mikkelsen,et al.  Phase IIa trial of cilengitide (EMD121974) single-agent therapy in patients (pts) with recurrent glioblastoma (GBM): EMD 121974-009 , 2007 .

[32]  H. Verheul,et al.  Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition , 2007, Nature Reviews Cancer.

[33]  T. Mikkelsen,et al.  Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme , 2007, Investigational New Drugs.

[34]  D. Hicklin,et al.  Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. , 2007, Cancer research.

[35]  G. Yancopoulos,et al.  VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. , 2007, International journal of radiation oncology, biology, physics.

[36]  R. Jove,et al.  Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. , 2007, Cancer research.

[37]  Darell D. Bigner,et al.  Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma , 2007, Clinical Cancer Research.

[38]  Gavin Thurston,et al.  Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis , 2006, Nature.

[39]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[40]  M. Westphal,et al.  A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo , 2006, Clinical Cancer Research.

[41]  Qiulian Wu,et al.  Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. , 2006, Cancer research.

[42]  Howard A. Fine,et al.  Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 , 2006, Clinical Cancer Research.

[43]  Denis Lacombe,et al.  Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  T. Cloughesy,et al.  MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy , 2006, Neurology.

[45]  E. Holland,et al.  Platelet-derived growth factor (PDGF) and glial tumorigenesis. , 2006, Cancer letters.

[46]  Napoleone Ferrara,et al.  Angiogenesis as a therapeutic target , 2005, Nature.

[47]  Ricky T. Tong,et al.  Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Amanda J. Thomas,et al.  A Feasibility Trial of Antiangiogenic (Metronomic) Chemotherapy in Pediatric Patients With Recurrent or Progressive Cancer , 2005, Journal of pediatric hematology/oncology.

[49]  Masakazu Toi,et al.  Angiogenic inhibitors: a new therapeutic strategy in oncology , 2005, Nature Clinical Practice Oncology.

[50]  T. Mikkelsen,et al.  Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. , 2005, Neuro-oncology.

[51]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[52]  A. Friedman,et al.  Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma , 2005, Cancer.

[53]  Thomas Hartmann,et al.  Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. , 2004, Cancer cell.

[54]  D. Kaplan,et al.  SRC regulates actin dynamics and invasion of malignant glial cells in three dimensions. , 2004, Molecular cancer research : MCR.

[55]  Susan M. Chang,et al.  Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. , 2004, International journal of radiation oncology, biology, physics.

[56]  M. Prados,et al.  Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. , 2004, International journal of radiation oncology, biology, physics.

[57]  E. Maher,et al.  Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  D. Hanahan,et al.  Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. , 2003, The Journal of clinical investigation.

[59]  Q. Li,et al.  Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. , 2003, Anticancer research.

[60]  G. Yancopoulos,et al.  VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[61]  M. Westphal,et al.  Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. , 2001, Cancer research.

[62]  N. Pavlakis,et al.  Phase II study of Thalidomide in the treatment of recurrent glioblastoma multiforme , 2001, Journal of Neuro-Oncology.

[63]  D. Osoba,et al.  A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse , 2000, British Journal of Cancer.

[64]  M. Westphal,et al.  Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. , 2000, Neoplasia.

[65]  J. Folkman,et al.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.

[66]  P. Wen,et al.  Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  Susan M. Chang,et al.  Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  M J Gleason,et al.  Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[70]  M. Westphal,et al.  Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis , 1999, International journal of cancer.

[71]  Shay Soker,et al.  Characterization of Novel Vascular Endothelial Growth Factor (VEGF) Receptors on Tumor Cells That Bind VEGF via Its Exon 7-encoded Domain (*) , 1996, The Journal of Biological Chemistry.

[72]  R. D'Amato,et al.  Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[73]  A. Ullrich,et al.  Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.

[74]  Georg Breier,et al.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.

[75]  D. Stefanik,et al.  Acidic and basic fibroblast growth factors are present in glioblastoma multiforme. , 1991, Cancer research.

[76]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[77]  P. Wen,et al.  A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. , 2009, International journal of radiation oncology, biology, physics.

[78]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[79]  M. Westphal,et al.  Invasion as limitation to anti-angiogenic glioma therapy. , 2003, Acta neurochirurgica. Supplement.

[80]  M. Prados,et al.  Highly anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1989. , 1992, International journal of radiation oncology, biology, physics.